Transgene S.a.

Imaxio

Transgene

Jean-Baptiste Marchand

Nathalie Silvestre

Michel Geist

Christine Thioudellet

Perrine Martin

Benoît Grellier

Fergal Hill

Hélène Haegel

Karola Rittner

Laurence Dumon

François Penin

Kaïdre Bendjama

Hèléne Haegel

Cécile Beny

Marie Gouanvic

Geneviève Inchaupse

Charles Antoine Coupet

Romain Micol

Emmanuel Tupin

The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.

Personalized vaccine

The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Oncolytic virus for expression of immune checkpoint modulators

The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of aspecies, particularly aof the tuberculosis complex such as(Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against ainfection or any disease caused by or associated with ainfection.

Fusion of heterooligomeric mycobacterial antigens

The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.

Methods for treating or preventing HBV infection or HBV related diseases

The present invention relates generally to immunogenic combinations comprising at least five antigens of aspecies as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against ainfection or any disease caused by or associated with ainfection. The present invention also concerns antibodies directed to such mycobacterial antigens and fusion polypeptides that can be used in the diagnosis of ainfection and method of detection as well as kits of reagent comprising said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions or antibodies.

Mycobacterial antigen vaccine

HBV polymerase mutants

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Antibody against the CSF-1R

The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.

Methods of using multimeric complexes of antigens and an adjuvant

Multimeric complexes of antigens and an adjuvant

Growing community of inventors

Obernai, France

Jean-Baptiste Marchand